Woodline Partners’s Vor Biopharma VOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.71M Sell
194,242
-185,481
-49% -$3.96M 0.01% 796
2026
Q2
$6.99M Buy
+379,723
New +$5.75M 0.02% 609
2025
Q4
– Sell
-27,363
Closed -$1.33M – 1123
2025
Q3
$1.33M Buy
+27,363
New +$1.1M 0.01% 778
2024
Q2
– Sell
-55,556
Closed -$2.63M – 680
2024
Q1
$2.63M Hold
55,556
– – 0.02% 412
2023
Q4
$2.5M Hold
55,556
– – 0.03% 367
2023
Q3
$2.36M Hold
55,556
– – 0.03% 384
2023
Q2
$3.43M Hold
55,556
– – 0.04% 350
2023
Q1
$5.98M Hold
55,556
– – 0.08% 265
2022
Q4
$7.39M Hold
55,556
– – 0.1% 259
2022
Q3
$4.42M Hold
55,556
– – 0.06% 321
2022
Q2
$5.52M Hold
55,556
– – 0.09% 246
2022
Q1
$6.71M Hold
55,556
– – 0.11% 216
2021
Q4
$12.9M Hold
55,556
– – 0.18% 154
2021
Q3
$17.4M Sell
55,556
-1,769
-3% -$526K 0.28% 100
2021
Q2
$21.4M Sell
57,325
-338
-0.6% -$167K 0.4% 64
2021
Q1
$49.7M Buy
+57,663
New +$48.8M 1.1% 14

Other funds holding VOR

Woodline Partners's VOR Position: Q3 2026 in Review

Woodline Partners reduced its Vor Biopharma (VOR) stake by 49% in Q3 2026, selling an estimated $3.96M and leaving 194,242 shares worth $3.71M. The position accounts for 0.01% of the portfolio, ranked #796.

Woodline Partners first reported a position in VOR in Q1 2021 and has held it in 16 quarters since. The position peaked at $49.7M in Q1 2021. 105 funds tracked by Wall St. Rank hold VOR as of Q3 2026.

  • Woodline Partners held 194,242 shares of Vor Biopharma worth $3.71M as of Q3 2026.
  • Woodline Partners sold 185,481 Vor Biopharma shares in Q3 2026, an estimated $3.96M.
  • Vor Biopharma made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #796 holding.
  • Woodline Partners first reported a position in Vor Biopharma in Q1 2021 and has held it in 16 quarters since.
  • Woodline Partners's Vor Biopharma position peaked at $49.7M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.